RegeneRx Biopharmaceuticals Enrolled First Patient in the Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259 in the US
On April 12, 2023, RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company") announced that the first patient of Phase 3 clinical trial (SEER-2) of RGN-259, a novel treatment for neurotrophic keratitis (NK), has been enrolled and begun treatment. The product candidate, RGN-259, is under development by ReGenTree, LLC, a U.S. joint venture between RegeneRx and HLB Therapeutics.
RGN-259 is a novel drug candidate that promotes cell migration, anti-inflammation, and wound healing and whose active ingredient is thymosin beta 4...
